PK of immunoconjugate anticancer agent CMD-193 in rats: ligand-binding assay approach to determine in vivo immunoconjugate stability.

BACKGROUND: Antibody-drug conjugates (ADCs) are a new generation of anticancer therapeutics. The objective of this manuscript is to propose a methodology that can be used to assess the stability of the ADCs by using the PK data obtained by ligand-binding assays that measure various components of ADCs. RESULTS: The ligand-binding assays format of different components of ADCs provided unique valuable PK information. The mathematical manipulation of the bioanalytical data provided an insight into the in vivo integrity, indicating that the loading of the calicheamicin on the G193 antibody declines in an apparent slow first-order process. CONCLUSION: This report demonstrates the value of analyzing various components of the ADC and their PK profiles to better understand the disposition and in vivo stability of ADCs.

Simultaneous determination of lidamycin enediyne chromophore (LDC) and its aromatized derivative (LDCA) using puerarin as internal standard in rat plasma by LC-MS/MS.

Lidamycin (LDM), a promising enediyne antitumor antibiotic, was quantified by detecting lidamycin enediyne chromophore (LDC) using liquid chromatography-tandem mass spectrometry (LC-MS/MS) for the first time. A simple, rapid and reliable method was developed and validated to determine LDC and its aromatized derivative (LDCA) simultaneously in plasma. Puerarin was used as an internal standard (IS), and plasma samples were pretreated with one-step precipitation by acetonitrile. Separation was achieved on a reverse-phase C(18) column with a mobile phase composed of methanol and water containing 5 mm ammonium acetate at pH 3.5 in gradient elution mode. Detection was performed on a triple quadrupole tandem mass spectrometer using electrospray ionization (ESI) by multiple reaction monitoring (MRM) in the negative ion mode. Good linearity was obtained over the concentration range of 0.2-100 µg/mL for LDM. Precision and accuracy were validated by RSD% values in the range of 2.6-13.0% and RE% values between -4.6 and 3.8%, respectively. In addition, no specificity and matrix effects were observed. The recovery was found to be 99.2-111.0% and stability in various conditions was found to be acceptable. This method was applied in preclinical pharmacokinetic studies for routine monitoring of LDM in rat plasma.

[Lidamycin metabolism in vitro].

This paper is to report the study of the metabolism of lidamycin in vitro including in plasma and microsomes to guide clinical therapy. Lidamycin was quantified by detecting its active ingredient using HPLC-MS/MS. The metabolic stability of lidamycin in rat, Beagle dog, monkey and human plasma and liver microsomes, and its inhibition to cytochrome P450 isoforms in human liver microsomes were studied. Results showed that lidamycin was metabolized in the four species of plasma, and the sequence of metabolic rates in plasma were in rat > in dog > in human > in monkey. But among the four species of liver microsomes, lidamycin was metabolized only in monkey liver microsomes. There was almost no inhibition to cytochrome P450 isoforms at the concentrations of between 0.0005 and 10 ng x mL(-1). Therefore, the property of lidamycin metabolism in human is similar with that in dog, and metabolism of other drugs would not be decreased by cytochrome P450 as used along with lidamycin in clinic.